Global Bronchiectasis Market, By Disease Type (CF Bronchiectasis, Non-CF Bronchiectasis), Severity (Mild to Moderate, Moderate-to-Severe), Type (Diagnosis, Treatment), Drugs Type (Branded, Generics), Route of Administration (Oral, Parenteral, Inhalation), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2031.
Bronchiectasis Market Analysis and Size
As per a survey by the U.S. Medicare population, approximately 350,000 to 500,000 adults are affected by bronchiectasis in the U.S. The prevalence of bronchiectasis is age-dependent, with a notable 8- to 10-fold difference in prevalence observed after the age of 60 years, which is around 300 to 500 per 100,000, compared to individuals aged <40 to 50 years, which is around 40 to 50 per 100,000.
Data Bridge Market Research analyzes that the global bronchiectasis market, which was USD 562.92 million in 2023, is likely to reach USD 959.15 million by 2031 and is expected to undergo a CAGR of 6.1% during the forecast period. “Knowledge based” dominates the type segment of the bronchiectasis market due to the growing demand for better methods for treatment in patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD million, Volumes in Units, and Pricing in USD
|
|
Segments Covered
|
By Disease Type (CF Bronchiectasis, Non-CF Bronchiectasis), Severity (Mild to Moderate, Moderate-to-Severe), Type (Diagnosis, Treatment), Drugs Type (Branded, Generics), Route of Administration (Oral, Parenteral, Inhalation), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East & Africa
|
|
Market Players Covered
|
Abbott (U.S.), HERSILL (Spain), Inogen, Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), Medline Industries, Inc (U.S.), Ache Laboratories Farmaceuticos S.A. (Brzail), Horizon Therapeutics plc (Ireland), Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.) (U.S.), Trudell Medical International (Canada), GlaxoSmithKline plc. (U.S.), AstraZeneca (U.K.), Pfizer Inc. (U.S.), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical USA Inc.(A Subsidiary of Teva Pharmaceutical Industries Ltd.) (Israel), Sun Pharmaceutical Industries Ltd. (India), Bayer AG (Germany), Dr. Reddy’s Laboratories Ltd. (India), Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.) (U.S.), Viatris Inc. (U.S.), Covis Pharma (Switzerland), Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila) (U.S.), Cipla Inc. (India), Electromed, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Bronchiectasis is a term derived from Greek word bronckos which means airways and ectasis means widening. It is a chronic lung condition which is defined as abnormal and irreversible dilation of the bronchi in which both the muscular and elastic tissues are destroyed due to short-term and long-term infection. The combination of these infections leads to one or both lungs damage. The damage site is diagnosed by high resolution computed tomography (HRCT) scan in which it shows that the larger airways are mostly affected and in the smaller airways, the disease are not scanned that’s why some of the patients deals with symptoms for many years before the diagnosis.
Global Bronchiectasis Market Dynamics
Drivers
- Increasing Prevalence of Bronchiectasis
The rising prevalence of bronchiectasis, often due to respiratory infections, chronic obstructive pulmonary disease (COPD), or other underlying conditions, is a significant driver. As the number of affected individuals increases, so does the demand for diagnostics and treatments.
- Development of Targeted Therapies
Research and development efforts in the pharmaceutical industry have led to the development of more targeted therapies for bronchiectasis. These therapies are expected to improve patient outcomes and can boost the market.
Opportunities
- Unmet Medical Needs
There is a substantial unmet medical need in the bronchiectasis market, particularly for effective treatments that can slow disease progression, reduce exacerbations, and improve patients' quality of life. Developing novel therapies to address these needs presents a significant opportunity.
- Telemedicine and Remote Monitoring
Telemedicine and remote monitoring solutions can improve patient access to care, enhance disease management, and reduce hospitalizations. This presents opportunities for companies providing telehealth platforms and remote monitoring devices.
Restraints/Challenges
- Complex Disease Pathophysiology
Bronchiectasis is a complex and heterogeneous disease with various underlying causes, making it challenging to develop standardized treatment approaches. Tailoring treatments to individual patients is difficult. This can be a restraint for the market.
- High Healthcare Costs
The management of bronchiectasis, including frequent hospitalizations and the need for long-term care, can lead to high healthcare costs, impacting both patients and healthcare systems. This creates challenges for the market growth.
This bronchiectasis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bronchiectasis market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Development
- In July 2019, Pfizer Inc. completed the acquisition of Array BioPharma Inc., a company focused on the discovery, development and commercialization of variety of medicines indicated for treatment of several kinds of diseases. This acquisition boosted the company’s research and development activities and advanced it product portfolio
Global Bronchiectasis Market Scope
The bronchiectasis market is segmented on the disease type, severity, type, drugs type, route of administration, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- CF Bronchiectasis
- Non-CF Bronchiectasis
Severity
- Mild to Moderate
- Moderate-to-Severe
Type
- Diagnosis
- Treatment
Drugs Type
- Branded
- Generics
Route of Administration
- Oral
- Parenteral
- Inhalation
End User
- Hospitals
- Clinics
- Home Healthcare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Bronchiectasis Market Regional Analysis/Insights
The bronchiectasis market is analyzed and market size insights and trends are provided by country, disease type, severity, type, drugs type, route of administration, end user and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Brazil, Argentina, rest of South America, Germany, France, Italy, U.K., Belgium, Spain, Russia, Turkey, Netherlands, Switzerland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, U.A.E., Saudi Arabia, Egypt, South Africa, Israel, and rest of Middle East and Africa.
North America is expected to dominate the market due to the increasing clinical trials and research development for prevention of serious respiratory diseases among the adults.
Asia-Pacific is expected to witness significant growth during the forecast period of 2024 to 2031 due to the rise in prevalence of respiratory diseases such as asthma, COPD, tuberculosis and rising geriatric population and increasing demand of effective treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Bronchiectasis Market Share Analysis
The bronchiectasis market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the bronchiectasis market.
Some of the major players operating in the bronchiectasis market are:
- Abbott (U.S.)
- HERSILL (Spain)
- Inogen, Inc. (U.S.)
- Boehringer Ingelheim International GmbH (Germany)
- Medline Industries, Inc (U.S.)
- Ache Laboratories Farmaceuticos S.A. (Brazil)
- Horizon Therapeutics plc (Ireland)
- Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.) (U.S.)
- Trudell Medical International (Canada)
- GlaxoSmithKline plc. (U.S.)
- AstraZeneca (U.K.)
- Pfizer Inc. (U.S.)
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) (Israel)
- Sun Pharmaceutical Industries Ltd. (India)
- Bayer AG (Germany)
- Dr. Reddy’s Laboratories Ltd. (India)
- Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma Co., Ltd.) (U.S.)
- Viatris Inc. (U.S.)
- Covis Pharma (Switzerland)
- Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila) (U.S.)
- Cipla Inc. (India)
- Electromed, Inc. (U.S.)
SKU-